Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction

Abstract

Nicotinamide adenine dinucleotide (NAD) is a REDOX cofactor and metabolite essential for neuronal survival. Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline. Repleting NAD via dietary supplementation of nicotinamide (a precursor to NAD) is effective in preventing retinal ganglion cell neurodegeneration in mouse models. Supporting this, short-term oral nicotinamide treatment in human glaucoma patients provides a recovery of retinal ganglion cell function implying a protection of visual function. Despite this, the mechanism of neuroprotection and full effects of nicotinamide on retinal ganglion cells is unclear. Glaucoma is a complex neurodegenerative disease in which a mix of healthy, stressed, and degenerating retinal ganglion cells co-exist, and in which retinal ganglion cells display compartmentalized degeneration across their visual trajectory. Therefore, we assess the effects of nicotinamide on retinal ganglion cells in normal physiological conditions and across a range of glaucoma relevant insults. We confirm neuroprotection afforded by nicotinamide in rodent models which represent isolated ocular hypertensive, axon degenerative, and mitochondrial degenerative insults. We define a small molecular weight metabolome for the retina, optic nerve, and superior colliculus which demonstrates that ocular hypertension induces widespread metabolic disruption that can be prevented by nicotinamide. Nicotinamide provides these neuroprotective effects by increasing oxidative phosphorylation, buffering and preventing metabolic stress, and increasing mitochondrial size and motility whilst simultaneously dampening action potential firing frequency. These data support continued determination of the utility of long-term NAM treatment as a neuroprotective therapy for human glaucoma. One Sentence Summary The NAD precursor nicotinamide has a potent neuroprotective effect in the retina and optic nerve, targeting neuronal function, metabolism, and mitochondrial function.

References 88

1. 1.

   Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090.

   Not in our library10.1016/j.ophtha.2014.05.013

2. 2.

   Naik S., Pandey A., Lewis S.A., Rao B.S.S., Mutalik S. Neuroprotection: a versatile approach to combat glaucoma. Eur. J. Pharmacol. 2020;881:173208.

   Not in our library10.1016/j.ejphar.2020.173208

3. 3.

   Peters D., Bengtsson B., Heijl A. Factors associated with lifetime risk of open-angle glaucoma blindness. Acta Ophthalmol. 2014;92(5):421-425.

   Not in our library10.1111/aos.12203

4. 4.

   Tribble J.R., Vasalauskaite A., Redmond T., Young R.D., Hassan S., Fautsch M.P. Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma. Brain Commun. 2019;1(1):fcz035.

   Not in our library10.1093/braincomms/fcz035

5. 5.

   Williams P.A., Harder J.M., Foxworth N.E., Cochran K.E., Philip V.M., Porciatti V. Vitamin B-3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756-760.

   Not in our library10.1126/science.aal0092

6. 6.

   Kouassi Nzoughet J., Chao de la Barca J.M., Guehlouz K., Leruez S., Coulbault L., Allouche S. Nicotinamide deficiency in primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2019;60(7):2509-2514.

   Not in our library10.1167/iovs.19-27099

7. 7.

   Hui F., Tang J., Williams P.A., McGuinness M.B., Hadoux X., Casson R.J. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin. Exp. Ophthalmol. 2020;48(7):903-914.

   Not in our library10.1111/ceo.13818

8. 8.

   Poljsak B., Milisav I. Vitamin B3 forms as precursors to NAD+: are they safe? Trends Food Sci. Technol. 2018;79:198-203.

   Not in our library

9. 9.

   Knip M., Douek I.F., Moore W.P., Gillmor H.A., McLean A.E., Bingley P.J. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43(11):1337-1345.

   Not in our library10.1007/s001250051536

10. 10.

    Morgan J.E. Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review. Clin. Exp. Ophthalmol. 2012;40(4):364-368.

    Not in our library10.1111/j.1442-9071.2012.02789.x

11. 11.

    Tribble J.R., Otmani A., Kokkali E., Lardner E., Morgan J.E., Williams P.A. Retinal ganglion cell degeneration in a rat magnetic bead model of ocular hypertensive glaucoma. Transl Vis Sci Technol. 2021;10(1):21.

    Not in our library10.1167/tvst.10.1.21

12. 12.

    Bull N.D., Johnson T.V., Welsapar G., DeKorver N.W., Tomarev S.I., Martin K.R. Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest. Ophthalmol. Vis. Sci. 2011;52(6):3309-3320.

    Not in our library10.1167/iovs.10-6873

13. 13.

    Binley K.E., Ng W.S., Barde Y.A., Song B., Morgan J.E. Brain-derived neurotrophic factor prevents dendritic retraction of adult mouse retinal ganglion cells. Eur. J. Neurosci. 2016;44(3):2028-2039.

    Not in our library10.1111/ejn.13295

14. 14.

    Zhang X., Jones D., Gonzalez-Lima F. Neurodegeneration produced by rotenone in the mouse retina: a potential model to investigate environmental pesticide contributions to neurodegenerative diseases. J. Toxicol. Environ. Health. 2006;69(18):1681-1697.

    Not in our library10.1080/15287390600630203

15. 15.

    Cimdins K., Waugh H.S., Chrysostomou V., Lopez Sanchez M.I.G., Johannsen V.A., Cook M.J. Amyloid precursor protein mediates neuronal protection from rotenone toxicity. Mol. Neurobiol. 2019;56(8):5471-5482.

    Not in our library10.1007/s12035-018-1460-7

16. 16.

    Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9(7):676-682.

    Not in our library10.1038/nmeth.2019

17. 17.

    Wang L., Dong J., Cull G., Fortune B., Cioffi G.A. Varicosities of intraretinal ganglion cell axons in human and nonhuman primates. Invest. Ophthalmol. Vis. Sci. 2003;44(1):2-9.

    Not in our library10.1167/iovs.02-0333

18. 18.
    Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma · 2016

    No notice
19. 19.

    Quiros P.M., Goyal A., Jha P., Auwerx J. Analysis of mtDNA/nDNA ratio in mice. Curr Protoc Mouse Biol. 2017;7(1):47-54.

    Not in our library10.1002/cpmo.21

20. 20.

    Xia J., Psychogios N., Young N., Wishart D.S. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 2009;37:W652-W660.

    Not in our library10.1093/nar/gkp356

21. 21.

    Xia J., Wishart D.S. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat. Protoc. 2011;6(6):743-760.

    Not in our library10.1038/nprot.2011.319

22. 22.
    Centering, scaling, and transformations: improving the biological information content of metabolomics data · 2006

    No notice
23. 23.

    Gu Z., Gu L., Eils R., Schlesner M., Brors B. Circlize Implements and enhances circular visualization in R. Bioinformatics. 2014;30(19):2811-2812.

    Not in our library10.1093/bioinformatics/btu393

24. 24.

    Misgeld T., Kerschensteiner M., Bareyre F.M., Burgess R.W., Lichtman J.W. Imaging axonal transport of mitochondria in vivo. Nat. Methods. 2007;4(7):559-561.

    Not in our library10.1038/nmeth1055

25. 25.

    Burgess R.W., Fuerst P.G. Distinct expression patterns of mitochondrially localized YFP in neuronal subsets in the retina of three transgenic mouse lines. BMC Res. Notes. 2010;3:253.

    Not in our library10.1186/1756-0500-3-253

26. 26.

    Sun S., Erchova I., Sengpiel F., Votruba M. Opa1 deficiency leads to diminished mitochondrial bioenergetics with compensatory increased mitochondrial motility. Invest. Ophthalmol. Vis. Sci. 2020;61(6):42.

    Not in our library10.1167/iovs.61.6.42

27. 27.

    Winzeler A., Wang J.T. Purification and culture of retinal ganglion cells from rodents. Cold Spring Harb. Protoc. 2013;2013(7):643-652.

    Not in our library10.1101/pdb.prot074906

28. 28.

    Neumann S., Chassefeyre R., Campbell G.E., Encalada S.E. KymoAnalyzer: a software tool for the quantitative analysis of intracellular transport in neurons. Traffic. 2017;18(1):71-88.

    Not in our library10.1111/tra.12456

29. 29.

    Skytt D.M., Toft-Kehler A.K., Brændstrup C.T., Cejvanovic S., Gurubaran I.S., Bergersen L.H. Glia-neuron interactions in the retina can Be studied in cocultures of müller cells and retinal ganglion cells. BioMed Res. Int. 2016;2016:1087647.

    Not in our library10.1155/2016/1087647

30. 30.

    Vohra R., Aldana B.I., Bulli G., Skytt D.M., Waagepetersen H., Bergersen L.H. Lactate-mediated protection of retinal ganglion cells. J. Mol. Biol. 2019;431(9):1878-1888.

    Not in our library10.1016/j.jmb.2019.03.005

31. 31.

    Nair A.B., Jacob S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 2016;7(2):27-31.

    Not in our library10.4103/0976-0105.177703

32. 32.

    Kasischke K., Büchner M., Ludolph A.C., Riepe M.W. Nuclear shrinkage in live mouse hippocampal slices. Acta Neuropathol. 2001;101(5):483-490.

    Not in our library10.1007/s004010000317

33. 33.

    Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.

    Not in our library10.1126/science.aac4854

34. 34.

    Tribble J.R., Kokkali E., Otmani A., Plastino F., Lardner E., Vohra R. When is a control not a control? Reactive microglia occur throughout the control contralateral pathway of retinal ganglion cell projections in experimental glaucoma. Transl Vis Sci Technol. 2021;10(1):22.

    Not in our library10.1167/tvst.10.1.22

35. 35.

    Coleman M.P., Höke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat. Rev. Neurosci. 2020;21(4):183-196.

    Not in our library10.1038/s41583-020-0269-3

36. 36.

    Béard E., Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. J. Neurochem. 2010;115(2):297-313.

    Not in our library10.1111/j.1471-4159.2010.06935.x

37. 37.

    Sia P.I., Wood J.P.M., Chidlow G., Casson R. Creatine is neuroprotective to retinal neurons in vitro but not in vivo. Invest. Ophthalmol. Vis. Sci. 2019;60(13):4360-4377.

    Not in our library10.1167/iovs.18-25858

38. 38.

    Tretter L., Adam-Vizi V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2005;360(1464):2335-2345.

    Not in our library10.1098/rstb.2005.1764

39. 39.

    Gibson G.E., Park L.C., Sheu K.F., Blass J.P., Calingasan N.Y. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem. Int. 2000;36(2):97-112.

    Not in our library10.1016/s0197-0186(99)00114-x

40. 40.

    Herrmann W., Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin. Chem. Lab. Med. 2011;49(3):435-441.

    Not in our library10.1515/cclm.2011.084

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.